http://neurodiderot.org/index.php/soussi-en/
Nadia Soussi-Yanicostas, PhD, HDR, and Research director at CNRS. She leads a team on Neurodevelopment & neurodevelpmental disorders in zebrafish at Université de Paris, in the INSERM unit U1141 at Robert Debré Hospital in Paris, France. In my team, we use zebrafish embryos as in vivo tools to better understand the interactions between neurons and microglial cells in different disease contexts, such as epilepsy and childhood encephalopathy, and following environmental insults, such as pesticide poisoning. Specifically, we use a multidisciplinary approach, combining zebrafish mutants, transgenic technologies, in vivo calcium imaging, electrophysiology, behavioural studies, and classic molecular biology methods of protein and RNA analysis, to: (i) precisely characterize the spectrum of microglia activities induced by different types of neuron dysfunctions resulting from either disease or poisoning, and (ii) better understanding the consequences of these microglia activities (neuro-inflammation and/or neuro-protection) on subsequent neuron physiology. Currently, the research activity of my team is focused on two main research projects. The first aims at investigating the activity of microglia in different genetic epilepsy contexts in zebrafish (using mutant lines scn1Lab-/-, depdc5-/-, gabra1-/- and gabrg2-/-, four genes that have been found mutated in human Dravet syndrome childhood epilepsy) and also better understand the consequences of this microglia activity on subsequent brain functioning and neuron excitability. In line with this research theme, using diisopropylfluorophodphate (DFP), a mildly toxic organophosphorus compound analogous to warfare agents Sarin and Soman, we are also investigating the mechanism underlying the epileptogenic effect of organophosphorus and seek identifying effective countermeasures. Our second project is in line with the recent demonstration in our laboratory that succinate dehydrogenase inhibitor (SDHI) molecules, the most widely used fungicides in agriculture practices today, are not fungus-specific and efficient inhibit SDH activity in honey bees, lumbrics and human cells. In our team we are studying the role of three SDHIs, which has never been estimated in in vivo models, on neurodevelopment and neurobehavior.
director research director Scientific coordinator
Nadia Soussi-Yanicostas
- CNRS Research Director and research group leader, Inserm U.1141 - NeuroDiderot, Paris, France
- Scientific coordinator of the Zebrafish Plateform for Robert Debré Hospital research units.
- Director of service offer Neuroscreen: High-throughput screening for psycho-active molecules in zebrafish embryos.
University degrees and qualifications :
2010 - today : Research group leader, Inserm U.1141, Paris, France
2005-2009 : Group leader Inserm-Avenir at Inserm U.6016, Salpêtriere hospital, Paris, France
2003 : Habilitation à Diriger des Recherches (HDR) (Paris 7 University), Paris, France
1994 : Research Associate at CNRS, Pasteur Institute, Paris, France
1993-1994 : Post-doctoral training Pasteur Institute, Paris (Pr. Christine Petit)
1991-1993 : Post-doctoral training Pasteur Institute, Paris (Pr. François Gros)
1988 -1991 : Ph.D. Doctorat in Sciences, (Paris 7 University), Paris, France
Publication Nadia Soussi-Yanicostas
1. Somkhit J, et al. and, Soussi-Yanicostas N.
Zebrafish. 2020 , May 4. doi: 10.1089/zeb.2020.1878.
2. Brenet A, et al. and N Soussi-Yanicostas..
Scientific Reports, Preprint. doi.org/10.1101/2019.12.15.876649.
3. Rahma Hassan-Abdi, Alexandre Brenet, and Nadia Soussi-Yanicostas.
Chemosphere, in revisio, doi: https://doi.org/10.1101/2020.08.15.252254
4. Brenet A, et al., and Soussi-Yanicostas N.
Cells. 2019; 8(10):1199. doi: 10.3390/cells8101199.
5. Hassan-Abdi R, et al., and , Soussi-Yanicostas N.
Front Neurosci. 2019;13.
6. Mairesse J, et al., and O Baud*, N Soussi-Yanicostas*. * last co-authors.
Glia. 2019;67(2):345-359.
7. Van Steenwinckel J, et al., and Soussi-Yanicostas N, Fleiss B, Gressens P.
Brain. 2019;142(12):3806-3833.
8. Samarut É, et al., Soussi-Yanicostas N, Drapeau P.
Epilepsia. 2018;(September):2061-2074.
9. Swaminathan et al., and N Soussi-Yanicostas , P Drapeau , E Samarut.
Curr Biol. 2018;28:1924-1937.
10. Auvin S, et al. and Soussi-Yanicostas N, Dournaud P, Sterkers G.
Epilepsia. 2018;59(4):e45-e50.
11. Alavi Naini SM, et al. and Soussi-Yanicostas N.
Transl Neurodegener. 2018;7(1).
12. Lebcir A, et al., Soussi-Yanicostas N.
Zebrafish. 2016 Dec;13(6):535-536.
13. Alavi Naini* SM, & a. and , Soussi-Yanicostas* N.
Brain. 2015;138(Pt 5):1339-54.
14. Ghoumid J, and al. and Soussi-Yanicostas N, Giurgea I.
Hum Mol Genet. 2013, 1;22(13):2652-61.
15. Yanicostas C, and al., and, Soussi-Yanicostas N.
PLoS One. 2012;7(11):e50705.
16. Martin E, and al., and Soussi-Yanicostas N.
Neurobiol Dis. 2012 Dec;48(3):299-308.
17. Ayari B, Landoulsi A, Soussi-Yanicostas N.
Brain Res Bull. 2012, Jul 1;88(4):345-53
18. Ayari B, El Hachimi KH, Yanicostas C, Landoulsi A, Soussi-Yanicostas N.
J Neurotrauma. 2010 May; 27(5):959-72.
19. García-González D, et al., and Soussi-Yanicostas N, de Castro F.
Exp Neurol. 2010 Apr;222(2):285-95.
20. Yanicostas C, et al., and , Soussi-Yanicostas N.
Mol Cell Endocrinol. 2009 Nov 27;312(1-2):53-60.
21. Puverel S, Nakatani H, Parras C, Soussi-Yanicostas N.
J Comp Neurol. 2009 Jan 10;512(2):232-42. doi: 10.1089/neu.2009.0972.
22. Bribián A, et al., and , Soussi-Yanicostas N, Thomas JL, Zalc B, de Castro F.
Dev Neurobiol. 2008 Nov;68(13):1503-16.
23. Clemente D, et al., and Soussi-Yanicostas N, Silva A, De Castro F.
Dev Dyn. 2008 Sep;237(9):2518-28.
24. Yanicostas C, et al., and Soussi-Yanicostas N.
Dev Biol. 2008 Aug 15;320(2):469-79. doi: 10.1016/j.ydbio.2008.06.008.
25. Ayari B, Soussi-Yanicostas N.
Dev Genes Evol. 2007 Feb;217(2):169-75.
26. Ernest S, Guadagnini S, Prévost MC, Soussi-Yanicostas N.
Gene Expr Patterns. 2007 Jan;7(3):274-81.
27. Bribián A, Barallobre MJ, Soussi-Yanicostas N, de Castro F.
Mol Cell Neurosci. 2006 Sep;33(1):2-14.
28. Dodé C, et al., and Soussi-Yanicostas N, et al., and Hardelin JP.
Nat Genet. 2003 Apr;33(4):463-5.
29. Dellovade TL, Hardelin JP, Soussi-Yanicostas N, Pfaff DW, Schwanzel-Fukuda M, Petit C.
Brain Res Dev Brain Res. 2003 Feb 16;140(2):157-67.
30. Soussi-Yanicostas N, et al.
Cell. 2002 Apr 19;109(2):217-28.
31. Hardelin JP, Julliard AK, Moniot B, Soussi-Yanicostas N, et al.
Dev Dyn. 1999 May;215(1):26-44.
32. Soussi-Yanicostas N, et al.
J Cell Sci. 1998 Oct;111 ( Pt 19):2953-65.
33. Soussi-Yanicostas N, et al.
J Cell Sci. 1996 Jul;109 ( Pt 7):1749-57. PMID: 8832397.
34. Hamida CB, Soussi-Yanicostas N, et al.
J Neurol Sci. 1994 May;123(1-2):114-21.
35. Ben Hamida C, Soussi-Yanicostas N, et al.
Muscle Nerve. 1994 Apr;17(4):400-10.
36. Soussi-Yanicostas N, Whalen RG, Petit C.
Hum Mol Genet. 1993 May;2(5):563-9.
37. Soussi-Yanicostas N, et al.
J Neurol Sci. 1992 May;109(1):111-20.
38. Soussi-Yanicostas N, Butler-Browne GS.
Dev Biol. 1991 Oct;147(2):374-80.
39. Soussi-Yanicostas N, et al.
J Neurol Sci. 1991 Jul;104(1):64-73.
40. Rotter M, Zimmerman K, Poustka A, Soussi-Yanicostas N, Starzinski-Powitz A.
Nucleic Acids Res. 1991 Apr 11;19(7):1497-504.
41. Laurent-Winter C, Soussi-Yanicostas N, Butler-Browne GS.
FEBS Lett. 1991 Mar 25;280(2):292-6.
42. Soussi-Yanicostas N, et al.
Neuromuscul Disord. 1991;1(2):103-11.
43. Soussi-Yanicostas N, et al.
Development. 1990 Feb;108(2):239-49.
44. Alavi Naini SM, Soussi-Yanicostas N.
Front Cell Dev Biol. 2018,;6:163.
45. Alavi Naini SM, Soussi-Yanicostas N.
Oxid Med Cell Longev. 2015; 2015:151979.
46 Yanicostas C, Soussi-Yanicostas N, El-Khoury R, Bénit P, Rustin P.
Semin Fetal Neonatal Med. 2011 Aug;16(4):175-80.
47. Hardelin JP, Soussi-Yanicostas N, Ardouin O, Levilliers J, Petit C.
Adv Otorhinolaryngol. 2000; 56:268-74.
48. Hardelin, J.-P., Soussi-Yanicostas, N., et al.
Advances in Nephrology 1998, 28, 419-428.
49. Hardelin JP, Soussi-Yanicostas N, et al.
Adv Nephrol Necker Hosp. 1998;28:419-28.
50. Soussi-Yanicostas N., et al.
Annales de l’Institut Pasteur 1995, 6, 282-291.
51. Soussi-Yanicostas N.
Bulletin de l’Institut Pasteur 1991, 89, 255-295.
52. Soussi-Yanicostas N., et al.
Muscle and Motility 1990, 2, 63-70.
3. Books
1. Coelho, M, Soussi-Yanicostas N, de Castro, F.
CHEMICAL SENSES 2006, Volume: 31, Issue: 8, Pages: E25.
2. Hardelin J-P., Soussi-Yanicostas N., Ardouin O., Levilliers J., Petit C. .
In Advances in Oto-Rhino-Laryngology 2000 , K. Kitamura and K.P. Steel, eds. (Basal, Karger, SA). 56, 268-274.
3. Hardelin J-P., Levilliers J., Soussi-Yanicostas N., Adbelhak S., Kalatzis V.,.Cohen-Salmon M., Petit C.
Actualités Néphrologiques 1998, Jean Hamburger, Grünefeld JP, Bach JF, & Kreis H, eds. Médecine-Sciences Flammarion. 333-340.
4. Books and Abstracts in conferences
- Soussi-Yanicostas N. Colloque recherche FIRENDO 2019- ‘Apport du modèle poisson zèbre (zebrafish) à l’étude des maladies rares’ ; Livret : Livret_bilan_Colloque_Recherche_2019_.pdf.
Lien : http://www.firendo.fr/fileadmin/user_upload/JAF2019/Livret_bilan_Colloque_Recherche_2019_.pdf
- Van Steenwinckel, J ; Schang, AL ; Krishnan, M ; Verdonk, F ; Chretien, F; Edwards, AD ; Hagberg, Soussi-Yanicostas N, HFleiss, B ; Gressens, P.
GLIA 2017, Volume: 65, Pages: E459-E459, Supplement: 1.
- Gressens, P ; Steenwinckel, JV ; Schang, AL ; Sigaut, S ; Degos, V; Lebon, S ; Schwendimann, L ; Charpentier, TL ; Hagberg, H; Soussi-Yanicostas N.
JOURNAL OF NEUROCHEMISTRY 2015, Volume: 134, Pages: 122-122, Supplement: 1, Special issue:S1.
- Fleiss, B; Van Steenwinckel, J; Schang, AL; Sigaut, S; Krishnan, M; Montame, A; Degos, V; Hennebert, O; Lebon, S; Schwendimann, L; Le Charpentier, T; Edwards, AD; Soussi-Yanicostas, N; Gressens, P.
GLIA 2015, Volume: 63 Pages: E367-E368 Supplement: 1 Meeting Abstract: T12-16B.
5. Patents
- Patent 1 : Soussi-Yanicostas N, Yanicostas C, Alavi-Naini MS. 2011. International patent (deposit number: PCT/EP2012106523). Materials and methods for the treatment of tauopathies. Ce brevet a été étendu aux Etats-Unis en Juin 2016 (N° de dépôt : 15/196,180).
- Patent 2 : Papy-Garcia D, Huyn B, Soussi-Yanicostas N, et al. 2012. European patent (deposit number: 12300005414.0-2107). Method of diagnosis, pronostic or treatment of neurodegenerative diseases. Ce brevet a été étendue aux Etats-Unis (Date de dépôt 01/06/2016, N° Dépôt 15/196,180), Déposant: SATT Ile-de-France Innov.
- Brevet 3 : Chritine Petit, Nadia Soussi-Yanicostas, et coll. (1998). Use of the KAL protein and treatment with the KAL protein in treatment of neural injury. Brevet déposé par l’Institut Pasteur (N°761,136).
Nadia Soussi-Yanicostas, PhD, HDR, and Research director at CNRS. She leads a team on Neurodevelopment & neurodevelpmental disorders in zebrafish at Université de Paris, in the INSERM unit U1141 at Robert Debré Hospital in Paris, France. In my team, we use zebrafish embryos as in vivo tools to better understand the interactions between neurons and microglial cells in different disease contexts, such as epilepsy and childhood encephalopathy, and following environmental insults, such as pesticide poisoning. Specifically, we use a multidisciplinary approach, combining zebrafish mutants, transgenic technologies, in vivo calcium imaging, electrophysiology, behavioural studies, and classic molecular biology methods of protein and RNA analysis, to: (i) precisely characterize the spectrum of microglia activities induced by different types of neuron dysfunctions resulting from either disease or poisoning, and (ii) better understanding the consequences of these microglia activities (neuro-inflammation and/or neuro-protection) on subsequent neuron physiology. Currently, the research activity of my team is focused on two main research projects. The first aims at investigating the activity of microglia in different genetic epilepsy contexts in zebrafish (using mutant lines scn1Lab-/-, depdc5-/-, gabra1-/- and gabrg2-/-, four genes that have been found mutated in human Dravet syndrome childhood epilepsy) and also better understand the consequences of this microglia activity on subsequent brain functioning and neuron excitability. In line with this research theme, using diisopropylfluorophodphate (DFP), a mildly toxic organophosphorus compound analogous to warfare agents Sarin and Soman, we are also investigating the mechanism underlying the epileptogenic effect of organophosphorus and seek identifying effective countermeasures. Our second project is in line with the recent demonstration in our laboratory that succinate dehydrogenase inhibitor (SDHI) molecules, the most widely used fungicides in agriculture practices today, are not fungus-specific and efficient inhibit SDH activity in honey bees, lumbrics and human cells. In our team we are studying the role of three SDHIs, which has never been estimated in in vivo models, on neurodevelopment and neurobehavior.
Senior Scientist at the High Council for the Evaluation of Research and Higher Education (HCERES) in Neurosciences
High Council for the Evaluation of Research and Higher Education (HCERES)
2018 - present
Scientific expert for the Research Executive Agency (REA).
The Research Executive Agency (REA)
2009 - present
CNRS Research Director and research group leader, Inserm U.1141 - NeuroDiderot, Paris, France
- Scientific coordinator of the Zebrafish Plateform for Robert Debré Hospital research units.
- Director of service offer Neuroscreen: High-throughput screening for psycho-active molecules in zebrafish embryos.
